These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

257 related items for PubMed ID: 10666187

  • 1. Effect of recombinant human erythropoietin combined with granulocyte/ macrophage colony-stimulating factor in the treatment of patients with myelodysplastic syndrome. GM/EPO MDS Study Group.
    Thompson JA, Gilliland DG, Prchal JT, Bennett JM, Larholt K, Nelson RA, Rose EH, Dugan MH.
    Blood; 2000 Feb 15; 95(4):1175-9. PubMed ID: 10666187
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
    Musto P, Sanpaolo G, D'Arena G, Scalzulli PR, Matera R, Falcone A, Bodenizza C, Perla G, Carotenuto M.
    Haematologica; 2001 Jan 15; 86(1):44-51. PubMed ID: 11146570
    [Abstract] [Full Text] [Related]

  • 4. An assessment of erythroid response to epoetin alpha as a single agent versus in combination with granulocyte- or granulocyte-macrophage-colony-stimulating factor in myelodysplastic syndromes using a meta-analysis approach.
    Mundle S, Lefebvre P, Vekeman F, Duh MS, Rastogi R, Moyo V.
    Cancer; 2009 Feb 15; 115(4):706-15. PubMed ID: 19152429
    [Abstract] [Full Text] [Related]

  • 5. Recombinant human erythropoietin in combined treatment with granulocyte- or granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes.
    Kasper C, Zahner J, Sayer HG.
    J Cancer Res Clin Oncol; 2002 Sep 15; 128(9):497-502. PubMed ID: 12242514
    [Abstract] [Full Text] [Related]

  • 6. Recombinant human granulocyte-macrophage colony-stimulating factor plus recombinant human erythropoietin may improve anemia in selected patients with myelodysplastic syndromes.
    Hansen PB, Johnsen HE, Hippe E, Hellström-Lindberg E, Ralfkiaer E.
    Am J Hematol; 1993 Dec 15; 44(4):229-36. PubMed ID: 8237992
    [Abstract] [Full Text] [Related]

  • 7. Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial.
    Della Porta MG, Garcia-Manero G, Santini V, Zeidan AM, Komrokji RS, Shortt J, Valcárcel D, Jonasova A, Dimicoli-Salazar S, Tiong IS, Lin CC, Li J, Zhang J, Pilot R, Kreitz S, Pozharskaya V, Keeperman KL, Rose S, Prebet T, Lai Y, Degulys A, Paolini S, Cluzeau T, Fenaux P, Platzbecker U.
    Lancet Haematol; 2024 Sep 15; 11(9):e646-e658. PubMed ID: 39038479
    [Abstract] [Full Text] [Related]

  • 8. Granulocyte and granulocyte-macrophage colony stimulating factors for newly diagnosed patients with myelodysplastic syndromes.
    Hutzschenreuter F, Monsef I, Kreuzer KA, Engert A, Skoetz N.
    Cochrane Database Syst Rev; 2016 Feb 16; 2(2):CD009310. PubMed ID: 26880256
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial.
    Platzbecker U, Della Porta MG, Santini V, Zeidan AM, Komrokji RS, Shortt J, Valcarcel D, Jonasova A, Dimicoli-Salazar S, Tiong IS, Lin CC, Li J, Zhang J, Giuseppi AC, Kreitz S, Pozharskaya V, Keeperman KL, Rose S, Shetty JK, Hayati S, Vodala S, Prebet T, Degulys A, Paolini S, Cluzeau T, Fenaux P, Garcia-Manero G.
    Lancet; 2023 Jul 29; 402(10399):373-385. PubMed ID: 37311468
    [Abstract] [Full Text] [Related]

  • 10. Measurement of serum cytokine levels in patients with myelodysplastic syndromes.
    Verhoef GE, De Schouwer P, Ceuppens JL, Van Damme J, Goossens W, Boogaerts MA.
    Leukemia; 1992 Dec 29; 6(12):1268-72. PubMed ID: 1280751
    [Abstract] [Full Text] [Related]

  • 11. Very low doses of GM-CSF administered alone or with erythropoietin in aplastic anemia.
    Kurzrock R, Talpaz M, Gutterman JU.
    Am J Med; 1992 Jul 29; 93(1):41-8. PubMed ID: 1626572
    [Abstract] [Full Text] [Related]

  • 12. A phase I/II study of sequential interleukin-3 and granulocyte-macrophage colony-stimulating factor in myelodysplastic syndromes.
    Nand S, Sosman J, Godwin JE, Fisher RI.
    Blood; 1994 Jan 15; 83(2):357-60. PubMed ID: 8286736
    [Abstract] [Full Text] [Related]

  • 13. Pharmacokinetics and pharmacodynamics of once-weekly subcutaneous epoetin alfa in critically ill patients: results of a randomized, double-blind, placebo-controlled trial.
    Vincent JL, Spapen HD, Creteur J, Piagnerelli M, Hubloue I, Diltoer M, Roman A, Stevens E, Vercammen E, Beaver JS.
    Crit Care Med; 2006 Jun 15; 34(6):1661-7. PubMed ID: 16607233
    [Abstract] [Full Text] [Related]

  • 14. Sequential administration of recombinant human granulocyte-macrophage colony-stimulating factor and human erythropoietin for treatment of myelodysplastic syndromes.
    Runde V, Aul C, Ebert A, Grabenhorst U, Schneider W.
    Eur J Haematol; 1995 Jan 15; 54(1):39-45. PubMed ID: 7859874
    [Abstract] [Full Text] [Related]

  • 15. A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes.
    Italian Cooperative Study Group for rHuEpo in Myelodysplastic Syndromes, Ferrini PR, Grossi A, Vannucchi AM, Barosi G, Guarnone R, Piva N, Musto P, Balleari E.
    Br J Haematol; 1998 Dec 15; 103(4):1070-4. PubMed ID: 9886322
    [Abstract] [Full Text] [Related]

  • 16. The role of erythropoietin in the anemia of myelodysplastic syndrome.
    Stein RS.
    Clin Lymphoma; 2003 Aug 15; 4 Suppl 1():S36-40. PubMed ID: 14556674
    [Abstract] [Full Text] [Related]

  • 17. Treatment of the anemia of aplastic anemia patients with recombinant human erythropoietin in combination with granulocyte colony-stimulating factor: a multicenter randomized controlled study. Multicenter Study Group.
    Bessho M, Hirashima K, Asano S, Ikeda Y, Ogawa N, Tomonaga M, Toyama K, Nakahata T, Nomura T, Mizoguchi H, Yoshida Y, Niitsu Y, Kohgo Y.
    Eur J Haematol; 1997 Apr 15; 58(4):265-72. PubMed ID: 9186538
    [Abstract] [Full Text] [Related]

  • 18. Recombinant human granulocyte-macrophage colony-stimulating factor plus erythropoietin for the treatment of cytopenias in patients with myelodysplastic syndromes.
    Stasi R, Pagano A, Terzoli E, Amadori S.
    Br J Haematol; 1999 Apr 15; 105(1):141-8. PubMed ID: 10233377
    [Abstract] [Full Text] [Related]

  • 19. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial.
    Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B, Epoetin Alfa Study Group.
    J Clin Oncol; 2001 Jun 01; 19(11):2865-74. PubMed ID: 11387359
    [Abstract] [Full Text] [Related]

  • 20. Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study.
    Balleari E, Rossi E, Clavio M, Congiu A, Gobbi M, Grosso M, Secondo V, Spriano M, Timitilli S, Ghio R.
    Ann Hematol; 2006 Mar 01; 85(3):174-80. PubMed ID: 16408206
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.